Clinical trial

Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC

NCT03201146

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2017-06-27

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2017-06-27Date precision: day

Registry last updated2017-11-17

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Lung Cancerunresolved

Non Small Cell Lung Cancerunresolved

Combination Chemotherapyunresolved

Apatinibunresolved

Interventions

Apatinib 250mgDRUG

Apatinib 500mgDRUG

Apatinib 750mgDRUG

Sponsors & collaborators

West China Hospitallead sponsor

Jiangsu HengRui Medicine Co., Ltd.collaborator

Mapped research locations

ChengduSichuan, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03201146 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.